Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Cancer stem cell niche: the place to be
Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518
Cited by
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Additionally, Sissung TM et.al (2010) reported that expression of ABCG2 provides resistance to 5-FU, and doxorubicin in various cancer cell types by expelling drugs outside and thus protecting them from apoptosis [122–125].”
BackgroundMetallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Yang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215
Liu, B., & Wang, H. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11321 · Cited by 56
Zhang, Y., Liu, X., Zhang, J., Xu, Y., Shao, J., Hu, Y., Shu, P., & Cheng, H. (2020) · Aging · doi:10.18632/aging.102929 · Cited by 37
Metadata
- Authors
- Hsu, H., Chen, M., Baskaran, R., Lin, Y., Day, C. H., Lin, Y., Tu, C., Vijaya Padma, V., Kuo, W., & Huang, C.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-01-23
- Volume
- 233
- Issue
- 7
- Pages
- 5458-5467
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2774495316
- Cited by
- 172
- References
- 2
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. https://app.cochat.ai/papers/10.1002/jcp.26406
- The paper
- Hsu, H., Chen, M., Baskaran, R., Lin, Y., Day, C. H., Lin, Y., Tu, C., Vijaya Padma, V., Kuo, W., & Huang, C. (2018). Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.26406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.